Kintara Therapeutics, Inc.

The momentum for this stock is not very good. Kintara Therapeutics, Inc. is not a good value stock. Kintara Therapeutics, Inc. has good growth characteristics. Kintara Therapeutics, Inc. is a mediocre stock to choose.

News

Kintara Therapeutics (NASDAQ:KTRA) Trading Down 18.2%

Ticker Report Kintara Therapeutics, Inc. (NASDAQ:KTRA - Get Free Report) dropped 18.2% during trading on Friday . The stock traded as low as $0.18 and last traded at $0.18. Approximately 3,752,684 shares traded...\n more…

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

PR Newswire TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor TuHURA Biosciences Enters into Exclusivity and Right of...\n more…

Kintara Therapeutics Outlines Progress and Potential Risks

TipRanks Financial Blog An announcement from Kintara Therapeutics (KTRA) is now available. Kintara Therapeutics and TuHURA Biosciences recently shared updates on their corporate and clinic...\n more…

Kintara Therapeutics, TuHURA provide update on corporate, clinical advancements

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Kintara Therapeutics, TuHURA provide update on recent advancements

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

PR Newswire Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones Kintara Therapeutics and TuHURA Biosciences Provide Update on...\n more…